Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Cash & Equivalents (2019 - 2025)

Silence Therapeutics (SLN) has disclosed Cash & Equivalents for 7 consecutive years, with $11.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 90.71% to $11.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $11.3 million through Dec 2025, down 90.71% year-over-year, with the annual reading at $11.3 million for FY2025, 90.71% down from the prior year.
  • Cash & Equivalents hit $11.3 million in Q4 2025 for Silence Therapeutics, down from $102.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $121.3 million in Q4 2024 to a low of $11.3 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $80.5 million across 5 years, with a median of $83.1 million in 2021.
  • Biggest five-year swings in Cash & Equivalents: soared 173.5% in 2021 and later crashed 90.71% in 2025.
  • Year by year, Cash & Equivalents stood at $99.1 million in 2021, then plummeted by 35.14% to $64.3 million in 2022, then rose by 4.3% to $67.1 million in 2023, then surged by 80.93% to $121.3 million in 2024, then plummeted by 90.71% to $11.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SLN at $11.3 million in Q4 2025, $102.2 million in Q3 2025, and $114.2 million in Q2 2025.